GSK vs MRK
GSK plc vs Merck & Co. — AI-powered side-by-side comparison
GSK
GSK plc
64
Insufficient Data
VS
| Metric | GSK | MRK |
|---|
| AI Score |
64
|
70
|
| Price |
$50.91
|
$130.34
|
| P/E Ratio |
15.80×
|
103.53×
|
| ROE |
35.0%
|
34.7%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
73.3%
|
75.4%
|
| Debt / Equity |
1.03×
|
1.29×
|
| Dividend Yield |
3.5%
|
2.6%
|
| RSI (14) |
39.2
|
64.5
|
| Beta |
0.3
|
0.207
|
| Expected Upside |
—
|
—
|
AI Committee View
Current Innellis committee reasoning for GSK versus MRK.
MRK leads by 6 points.
MRK scores 70/100 (Buy) versus GSK at 64/100 (Insufficient Data).
GSK Committee View
67% agreement
3 analysts
Some positive signals exist — vix regime is low -- calm backdrop supports risk-taking — but they are not yet strong enough to justify a Buy. The committee is monitoring for confirmation.
Bull Case
- VIX regime is low -- calm backdrop supports risk-taking — Macro
- Market regime is bullish (Bull market -- normal position sizing) — Macro
- News sentiment is positive (+0.27 across 20 articles, 14d) — News
Bear Case
- MACD histogram negative -- bearish momentum — Technical
MRK Committee View
75% agreement
4 analysts
The primary driver is 5 consecutive earnings beats -- consistent execution. Most analysts agree, and no major concerns are blocking a stronger rating.
Bull Case
- 5 consecutive earnings beats -- consistent execution — Growth
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- Price structure making higher highs and higher lows — Technical
Bear Case
- MACD histogram negative -- bearish momentum — Technical